Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 7/20 | 0.58 |
| ▸ | CTSG | P08311 | 5/20 | 0.50 |
| ▸ | ACP3 | P15309 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10260987 | 0.88 | CMA1 (0.45) | CMA1CTSGACP3ALDH1A1GAA | |
| SCHEMBL3654937 | 0.85 | CMA1 (0.57) | CMA1CTSGACP3ALDH1A1 | |
| SCHEMBL4131076 | 0.84 | CMA1 (0.53) | CMA1CTSGACP3MAPT | |
| SCHEMBL998867 | 0.84 | CMA1 (0.53) | CMA1CTSGACP3MAPT | |
| SCHEMBL407974 | 0.82 | CMA1 (0.61) | CMA1CTSGACP3MAPT | |
| SCHEMBL409905 | 0.80 | CMA1 (0.59) | CMA1CTSGACP3 | |
| SCHEMBL408723 | 0.80 | CMA1 (0.53) | CMA1CTSGACP3 | |
| SCHEMBL997566 | 0.80 | CMA1 (0.58) | CMA1CTSGACP3 | |
| SCHEMBL4140309 | 0.79 | CMA1 (0.67) | CMA1CTSGACP3MAPT | |
| SCHEMBL1001231 | 0.79 | CMA1 (0.70) | CMA1CTSGACP3GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| JP-2011500682-A | — | — | 2011-01-06 | — | — | JP | claimed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
| WO-2009051746-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | claimed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | disclosed |
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | disclosed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| EP-1716160-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | EP | disclosed |
| US-20050176769-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176769-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885CTSG 36/4885ACP3 770/4885 |
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885CTSG 36/4885ACP3 770/4885 |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | CMA1 1/4885CTSG 166/4885ACP3 64/4885 |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885CTSG 36/4885ACP3 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.